{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:47Z","timestamp":1790775527645,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.canlet.2024.216978","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T06:28:03Z","timestamp":1716532083000},"page":"216978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Targeting the ubiquitin pathway in lymphoid malignancies"],"prefix":"10.1016","volume":"594","author":[{"given":"Boheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-943X","authenticated-orcid":false,"given":"Pieter Johan","family":"Adam Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216978_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ncb3358","article-title":"The increasing complexity of the ubiquitin code","volume":"18","author":"Yau","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216978_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41580-021-00448-5","article-title":"Ubiquitin ligases: guardians of mammalian development","volume":"23","author":"Cruz","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrm2780","article-title":"Building ubiquitin chains: E2 enzymes at work","volume":"10","author":"Ye","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbamcr.2013.03.008","article-title":"Assembly of the 20S proteasome","volume":"1843","author":"Kunjappu","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat. Struct. Biol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1152\/physrev.00002.2013","article-title":"Deubiquitylases from genes to organism","volume":"93","author":"Clague","year":"2013","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume":"10","author":"Komander","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.molcel.2016.05.009","article-title":"MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes","volume":"63","author":"Abdul Rehman","year":"2016","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.canlet.2024.216978_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","article-title":"Deubiquitinases in cancer","volume":"23","author":"Dewson","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216978_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","article-title":"Mechanisms of deubiquitinase specificity and regulation","volume":"86","author":"Mevissen","year":"2017","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A genomic and functional inventory of deubiquitinating enzymes","volume":"123","author":"Nijman","year":"2005","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbcan.2017.09.002","article-title":"The roles of ubiquitin modifying enzymes in neoplastic disease","volume":"1868","author":"Kumari","year":"2017","journal-title":"Biochimica et biophysica acta Reviews on cancer"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev."},{"key":"10.1016\/j.canlet.2024.216978_bib17","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","article-title":"Burkitt lymphoma","volume":"8","author":"Lopez","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12672-021-00435-4","article-title":"Emerging roles of the HECT-type E3 ubiquitin ligases in hematological malignancies","volume":"12","author":"Delvecchio","year":"2021","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","article-title":"Deubiquitinases in hematological malignancies","volume":"9","author":"Lei","year":"2021","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2020.274258","article-title":"Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma","volume":"107","author":"Ma","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/omi.2016.0158","article-title":"Understanding epstein-barr virus life cycle with proteomics: a temporal analysis of ubiquitination during virus reactivation","volume":"21","author":"Lv","year":"2017","journal-title":"OMICS A J. Integr. Biol."},{"issue":"11\u201312","key":"10.1016\/j.canlet.2024.216978_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41417-018-0070-x","article-title":"High expression of UBE2T predicts poor prognosis and survival in multiple myeloma","volume":"26","author":"Zhang","year":"2019","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/modpathol.2016.128","article-title":"PELI1 expression is correlated with MYC and BCL6 expression and associated with poor prognosis in diffuse large B-cell lymphoma","volume":"29","author":"Choe","year":"2016","journal-title":"Mod. Pathol. : an official journal of the United States and Canadian Academy of Pathology, Inc"},{"issue":"38","key":"10.1016\/j.canlet.2024.216978_bib27","doi-asserted-by":"crossref","first-page":"40704","DOI":"10.18632\/oncotarget.5727","article-title":"UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression","volume":"6","author":"Hussain","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/leu.2010.138","article-title":"The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling","volume":"24","author":"Hussain","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ejh.12729","article-title":"The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells","volume":"98","author":"Xu","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"16","key":"10.1016\/j.canlet.2024.216978_bib30","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood-2013-12-546309","article-title":"Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients","volume":"124","author":"de Miranda","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.2019002102","article-title":"UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells","volume":"136","author":"Swenson","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.canlet.2024.216978_bib32","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/gcc.20949","article-title":"Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia","volume":"51","author":"Nicholson","year":"2012","journal-title":"Genes, chromosomes & cancer"},{"key":"10.1016\/j.canlet.2024.216978_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/1471-2407-12-457","article-title":"Deletion of the TNFAIP3\/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma","volume":"12","author":"Nomoto","year":"2012","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2024.216978_bib35","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1038\/emboj.2012.241","article-title":"Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-\u03baB regulation","volume":"31","author":"Tokunaga","year":"2012","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib36","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-10-1071","article-title":"Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma","volume":"17","author":"Slovak","year":"2011","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2016.238","article-title":"Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma","volume":"31","author":"Wurster","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajpath.2012.09.012","article-title":"HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms","volume":"182","author":"K\u00fc\u00e7\u00fck","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2024.216978_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.leukres.2016.04.007","article-title":"HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations","volume":"45","author":"Bouzelfen","year":"2016","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib40","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, metabolism, and cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib41","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1038\/s41467-020-20107-1","article-title":"TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"27","key":"10.1016\/j.canlet.2024.216978_bib42","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1038\/s41388-020-1345-x","article-title":"The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma","volume":"39","author":"Crawford","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216978_bib43","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1038\/ncomms6384","article-title":"CSN6 drives carcinogenesis by positively regulating Myc stability","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.canlet.2024.216978_bib44","doi-asserted-by":"crossref","first-page":"16199","DOI":"10.1074\/jbc.M111.335216","article-title":"Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability","volume":"287","author":"Baresova","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"46","key":"10.1016\/j.canlet.2024.216978_bib45","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1038\/s41388-021-02031-w","article-title":"USP29 coordinates MYC and HIF1\u03b1 stabilization to promote tumor metabolism and progression","volume":"40","author":"Tu","year":"2021","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030806","article-title":"Imaging-Based screening of deubiquitinating proteases identifies otubain-1 as a stabilizer of c-MYC","volume":"14","author":"Moree","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cbf.3702","article-title":"USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma","volume":"40","author":"Wu","year":"2022","journal-title":"Cell Biochem. Funct."},{"issue":"12","key":"10.1016\/j.canlet.2024.216978_bib48","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/0008-5472.CAN-19-2247","article-title":"FBXW7 triggers degradation of KMT2D to favor growth of diffuse large B-cell lymphoma cells","volume":"80","author":"Saffie","year":"2020","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib49","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-021-01494-w","article-title":"Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2","volume":"36","author":"Yang","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/onc.2013.571","article-title":"Oncogenic Y641 mutations in EZH2 prevent Jak2\/\u03b2-TrCP-mediated degradation","volume":"34","author":"Sahasrabuddhe","year":"2015","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23693","article-title":"USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma","volume":"35","author":"Ma","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"issue":"23","key":"10.1016\/j.canlet.2024.216978_bib52","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.2019000381","article-title":"MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer\/T-cell lymphoma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3324\/haematol.2019.234385","article-title":"Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma","volume":"106","author":"Sarkar","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2024.216978_bib54","article-title":"KDM2A targets PFKFB3 for ubiquitylation to inhibit the proliferation and angiogenesis of multiple myeloma cells","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.5108","article-title":"Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma","volume":"246","author":"Liu","year":"2018","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/CMR.15.3.414-429.2002","article-title":"NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions","volume":"15","author":"Caama\u00f1o","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/scbi.1997.0057","article-title":"Rel\/NF-kappa B and I kappa B proteins: an overview","volume":"8","author":"May","year":"1997","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2010-06-290437","article-title":"Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-\u03baB-inducing kinase while activating both canonical and alternative nuclear factor-\u03baB pathways","volume":"117","author":"Pham","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib59","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41556-018-0084-5","article-title":"Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2","volume":"20","author":"Choi","year":"2018","journal-title":"Nat. Cell Biol."},{"issue":"12","key":"10.1016\/j.canlet.2024.216978_bib60","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood.2020004918","article-title":"MYD88 L265P elicits mutation-specific ubiquitination to drive NF-\u03baB activation and lymphomagenesis","volume":"137","author":"Yu","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib61","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-\u03baB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0180-4","article-title":"USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-\u03baBp65","volume":"50","author":"Zhou","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"10.1016\/j.canlet.2024.216978_bib63","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI98765","article-title":"Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma","volume":"128","author":"Franqui-Machin","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib64","article-title":"HTLV-1 activates YAP via NF-\u03baB\/p65 to promote oncogenesis","volume":"119","author":"Zhao","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2011-08-374561","article-title":"Tcl1 interacts with Atm and enhances NF-\u03baB activation in hematologic malignancies","volume":"119","author":"Gaudio","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib66","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tibs.2012.11.007","article-title":"Linear ubiquitination: a newly discovered regulator of cell signalling","volume":"38","author":"Rieser","year":"2013","journal-title":"Trends Biochem. Sci."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib67","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2159-8290.CD-13-0915","article-title":"Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms","volume":"4","author":"Yang","year":"2014","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2016.03.006","article-title":"Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma","volume":"29","author":"Yang","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib69","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.2019002654","article-title":"LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells","volume":"136","author":"Jo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216978_bib70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib72","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expet Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib74","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1878-0261.12641","article-title":"NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma","volume":"14","author":"Xia","year":"2020","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib75","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41375-021-01129-0","article-title":"Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity","volume":"35","author":"Ray","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040923","article-title":"Constitutive activation of p62\/sequestosome-1-mediated proteaphagy regulates proteolysis and impairs cell death in bortezomib-resistant mantle cell lymphoma","volume":"14","author":"Quinet","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.canlet.2024.216978_bib77","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","article-title":"A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells","volume":"11","author":"Milan","year":"2015","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib78","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/carcin\/bgab086","article-title":"DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination","volume":"42","author":"Zhang","year":"2021","journal-title":"Carcinogenesis"},{"issue":"18","key":"10.1016\/j.canlet.2024.216978_bib79","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1182\/bloodadvances.2021004315","article-title":"DKK1 activates noncanonical NF-\u03baB signaling via IL-6-induced CKAP4 receptor in multiple myeloma","volume":"5","author":"Li","year":"2021","journal-title":"Blood advances"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib80","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41388-019-1037-6","article-title":"Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma","volume":"39","author":"Xie","year":"2020","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib81","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00432-016-2216-2","article-title":"Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity","volume":"142","author":"Vaiou","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.canlet.2024.216978_bib82","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.18632\/oncotarget.2193","article-title":"The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells","volume":"5","author":"Hamouda","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040843","article-title":"The mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma","volume":"13","author":"Maneix","year":"2021","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.canlet.2024.216978_bib84","doi-asserted-by":"crossref","first-page":"20621","DOI":"10.18632\/oncotarget.4139","article-title":"Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment","volume":"6","author":"Fristedt Duvefelt","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5483\/BMBRep.2014.47.5.134","article-title":"Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-\u03baB-mediated cell signals and\/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis","volume":"47","author":"Park","year":"2014","journal-title":"BMB reports"},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12032-021-01632-5","article-title":"Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma","volume":"39","author":"Zhang","year":"2022","journal-title":"Medical oncology (Northwood, London, England)"},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib87","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","article-title":"Inhibition of NGLY1 inactivates the transcription factor Nrf1 and potentiates proteasome inhibitor cytotoxicity","volume":"3","author":"Tomlin","year":"2017","journal-title":"ACS Cent. Sci."},{"issue":"7","key":"10.1016\/j.canlet.2024.216978_bib88","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-020-00344-9","article-title":"In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma","volume":"10","author":"Mitra","year":"2020","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092287","article-title":"Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation","volume":"10","author":"Chen","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib91","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41598-020-57698-0","article-title":"Silencing of SENP2 in multiple myeloma induces bortezomib resistance by activating NF-\u03baB through the modulation of I\u03baB\u03b1 sumoylation","volume":"10","author":"Xie","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib92","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s13238-017-0500-9","article-title":"Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-\u03baB signaling pathway","volume":"9","author":"Yang","year":"2018","journal-title":"Protein & cell"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/leu.2014.279","article-title":"MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.canlet.2024.216978_bib94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-020-00393-0","article-title":"Downregulation of PA28\u03b1 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma","volume":"10","author":"Gu","year":"2020","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib95","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.12452","article-title":"The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma","volume":"162","author":"Gu","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib96","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/mp2004143","article-title":"Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib","volume":"9","author":"Berkers","year":"2012","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib97","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-21-0005","article-title":"M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (\u03b25i) delivering efficacy in multiple myeloma models","volume":"20","author":"Sanderson","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"14","key":"10.1016\/j.canlet.2024.216978_bib98","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1021\/acs.jmedchem.1c00604","article-title":"Structure-Based optimization and discovery of M3258, a specific inhibitor of the immunoproteasome subunit LMP7 (\u03b25i)","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib99","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/BJ20100383","article-title":"Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit","volume":"430","author":"Blackburn","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2024.216978_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116182","article-title":"Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma","volume":"40","author":"Zhang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.canlet.2024.216978_bib101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12885-016-2285-2","article-title":"Oral proteasome inhibitor with strong preclinical efficacy in myeloma models","volume":"16","author":"Park","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2015.06.011","article-title":"Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma","volume":"366","author":"Zang","year":"2015","journal-title":"Cancer letters"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0609.2010.01450.x","article-title":"BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma","volume":"85","author":"Sterz","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib104","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14756366.2019.1594802","article-title":"Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells","volume":"34","author":"Ettari","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"35","key":"10.1016\/j.canlet.2024.216978_bib105","doi-asserted-by":"crossref","first-page":"25593","DOI":"10.1074\/jbc.M113.480574","article-title":"The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases","volume":"288","author":"Kikuchi","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.canlet.2024.216978_bib106","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib107","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib108","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10218","key":"10.1016\/j.canlet.2024.216978_bib109","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"10068","key":"10.1016\/j.canlet.2024.216978_bib110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"14","key":"10.1016\/j.canlet.2024.216978_bib111","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib112","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10262","key":"10.1016\/j.canlet.2024.216978_bib113","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"24","key":"10.1016\/j.canlet.2024.216978_bib114","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib115","first-page":"643","article-title":"Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress","volume":"38","author":"Kawaguchi","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib116","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3892\/ijo.2014.2773","article-title":"Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells","volume":"46","author":"Moriya","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib117","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","article-title":"Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells","volume":"42","author":"Moriya","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib118","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13045-018-0657-6","article-title":"Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA","volume":"11","author":"Heine","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib119","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.13315","article-title":"Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death","volume":"169","author":"Mishima","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216978_bib120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fonc.2019.00249","article-title":"MPT0G413, A novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41419-020-2414-3","article-title":"Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib","volume":"11","author":"Xu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib122","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib123","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbagen.2014.02.006","article-title":"A novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth","volume":"1840","author":"Cao","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"19","key":"10.1016\/j.canlet.2024.216978_bib124","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1158\/0008-5472.CAN-14-3370","article-title":"VR23: a quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin E-mediated centrosome amplification","volume":"75","author":"Pundir","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.15033","article-title":"Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity","volume":"180","author":"Fujii","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib126","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150217","article-title":"Control of Pim2 kinase stability and expression in transformed human haematopoietic cells","volume":"35","author":"Adam","year":"2015","journal-title":"Biosci. Rep."},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib127","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","article-title":"The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma","volume":"16","author":"Le Moigne","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib128","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/JLB.2A1017-420RR","article-title":"Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-\u03baB signaling pathway in multiple myeloma","volume":"104","author":"Yao","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib129","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1535-7163.MCT-20-0184","article-title":"Novel, selective inhibitors of USP7 uncover multiple mechanisms of antitumor activity in vitro and in vivo","volume":"19","author":"Ohol","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib131","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/aps.2017.119","article-title":"Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro","volume":"39","author":"Jing","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib132","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/imr.12247","article-title":"Protein ubiquitination in lymphoid malignancies","volume":"263","author":"Yang","year":"2015","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib133","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6168","key":"10.1016\/j.canlet.2024.216978_bib134","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science (New York, NY)"},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"issue":"7512","key":"10.1016\/j.canlet.2024.216978_bib136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216978_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib138","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","article-title":"ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib139","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","article-title":"CK1\u03b1 and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma","volume":"132","author":"Patil","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.canlet.2024.216978_bib140","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib141","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib142","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s42003-021-02801-y","article-title":"PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates","volume":"4","author":"Shimizu","year":"2021","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.canlet.2024.216978_bib143","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bjh.12338","article-title":"High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"161","author":"Heintel","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib144","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00277-016-2743-6","article-title":"Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression","volume":"95","author":"Jung","year":"2016","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib145","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib146","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-014-2063-7","article-title":"Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma","volume":"93","author":"Huang","year":"2014","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib147","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clml.2016.08.007","article-title":"Prognostic significance of cereblon expression in patients with multiple myeloma","volume":"16","author":"Bila","year":"2016","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib148","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00277-021-04517-9","article-title":"Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone","volume":"100","author":"Cai","year":"2021","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib149","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","article-title":"The clinical significance of cereblon expression in multiple myeloma","volume":"38","author":"Schuster","year":"2014","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.canlet.2024.216978_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122683","article-title":"The CRBN, CUL4A and DDB1 expression predicts the response to immunomodulatory drugs and survival of multiple myeloma patients","volume":"10","author":"Barankiewicz","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib151","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/leu.2016.384","article-title":"IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)","volume":"31","author":"Kr\u00f6nke","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib152","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.canlet.2024.216978_bib153","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.2020010452","article-title":"Cereblon enhancer methylation and IMiD resistance in multiple myeloma","volume":"138","author":"Haertle","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib154","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Franssen","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib156","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib157","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib158","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/10428194.2019.1689391","article-title":"Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed\/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium","volume":"61","author":"Iskierka-Ja\u017cd\u017cewska","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib159","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12157","article-title":"Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner","volume":"12","author":"Dimopoulos","year":"2018","journal-title":"Mol. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2024.216978_bib160","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nature medicine"},{"issue":"40","key":"10.1016\/j.canlet.2024.216978_bib161","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111391118","article-title":"USP15 antagonizes CRL4(CRBN)-mediated ubiquitylation of glutamine synthetase and neosubstrates","volume":"118","author":"Nguyen","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib162","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib163","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1038\/s41598-020-61027-w","article-title":"Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide","volume":"10","author":"Tateno","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib164","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","article-title":"A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib165","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","article-title":"The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma","volume":"81","author":"Heider","year":"2021","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib166","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood-2016-09-738872","article-title":"Multiple myeloma cells' capacity to decompose H(2)O(2) determines lenalidomide sensitivity","volume":"129","author":"Sebastian","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib167","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbrc.2015.11.116","article-title":"Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells","volume":"469","author":"Endo","year":"2016","journal-title":"Biochemical and biophysical research communications"},{"issue":"3","key":"10.1016\/j.canlet.2024.216978_bib168","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/2326-6066.CIR-20-0555","article-title":"The IKZF1-IRF4\/IRF5 Axis controls polarization of myeloma-associated macrophages","volume":"9","author":"Mougiakakos","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib169","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib170","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.canlet.2024.216978_bib171","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.canlet.2024.216978_bib172","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2021014701","article-title":"Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1","volume":"139","author":"Wu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216978_bib173","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2021.02.110","article-title":"Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma","volume":"549","author":"Zhao","year":"2021","journal-title":"Biochemical and biophysical research communications"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib174","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2024.216978_bib176","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41375-018-0044-x","article-title":"Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma","volume":"32","author":"Zhang","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib177","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib178","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2018.201483","article-title":"Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations","volume":"104","author":"Lim","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.canlet.2024.216978_bib179","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.canlet.2024.216978_bib180","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.canlet.2024.216978_bib181","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1039\/D0SC00167H","article-title":"Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders","volume":"11","author":"Steinebach","year":"2020","journal-title":"Chem. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib182","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216978_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112397","article-title":"Discovery of IAP-recruiting BCL-X(L) PROTACs as potent degraders across multiple cancer cell lines","volume":"199","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.canlet.2024.216978_bib184","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.9b00455","article-title":"From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1)","volume":"62","author":"Papatzimas","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.canlet.2024.216978_bib185","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib186","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.canlet.2024.216978_bib187","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41589-022-00971-2","article-title":"Deubiquitinase-targeting chimeras for targeted protein stabilization","volume":"18","author":"Henning","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"28","key":"10.1016\/j.canlet.2024.216978_bib188","doi-asserted-by":"crossref","first-page":"12934","DOI":"10.1021\/jacs.2c04824","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib189","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/bloodadvances.2018026880","article-title":"Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells","volume":"3","author":"Best","year":"2019","journal-title":"Blood advances"},{"issue":"12","key":"10.1016\/j.canlet.2024.216978_bib190","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1080\/10428194.2019.1616190","article-title":"Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells","volume":"60","author":"Best","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"14","key":"10.1016\/j.canlet.2024.216978_bib191","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","article-title":"Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma","volume":"133","author":"Zhuang","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib192","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2012-02-406074","article-title":"Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A","volume":"120","author":"Pulvino","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216978_bib193","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2017.09.011","article-title":"1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma","volume":"140","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.canlet.2024.216978_bib194","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/bloodadvances.2020003829","article-title":"Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis","volume":"5","author":"Pemmaraju","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.canlet.2024.216978_bib195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","article-title":"Phase I study of the novel investigational NEDD8-activating enzyme inhibitor Pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma","volume":"22","author":"Shah","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2024.216978_bib196","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","article-title":"Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53","volume":"27","author":"Saleh","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.216978_bib197","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","article-title":"A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ADRM1 as a therapy for cancer","volume":"24","author":"Anchoori","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.canlet.2024.216978_bib198","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.canlet.2024.216978_bib199","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-019-0224-6","article-title":"Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity","volume":"9","author":"Ray","year":"2019","journal-title":"Blood Cancer J."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T23:18:15Z","timestamp":1718147895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":199,"alternative-id":["S0304383524003720"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216978","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the ubiquitin pathway in lymphoid malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216978"}}